Reported resultsCompany-reported
What was reported
MALVERN, PA., May 5, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 5, 2026 · Open the source ↗
What the evidence supports
Neuronetics published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $34.5 million | “• First quarter 2026 revenue of $34.5 million, up 8% compared to the first quarter 2025” Mentions: revenue |
| $21.5 million | “• U.S. clinic revenue of $21.5 million, up 15% compared to the first quarter 2025” Mentions: revenue |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineNeuronetics Reports First Quarter 2026 Financial and Operating ResultsU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 5, 2026 · Open the source ↗
Press release lead paragraphMALVERN, PA., May 5, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 5, 2026 · Open the source ↗
Amount stated in press release• First quarter 2026 revenue of $34.5 million, up 8% compared to the first quarter 2025U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 5, 2026 · Open the source ↗
Amount stated in press release• U.S. clinic revenue of $21.5 million, up 15% compared to the first quarter 2025U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 5, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:51 UTC
Neuronetics Reports First Quarter 2026 Financial and Operating Results
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.